NVCR NovoCure Limited

95.65
+3.07  (+3%)
Previous Close 92.58
Open 93
Price To Book 49.82
Market Cap 9,466,340,277
Shares 98,968,534
Volume 1,528,300
Short Ratio
Av. Daily Volume 943,405
Stock charts supplied by TradingView

NewsSee all news

  1. Novocure Announces National Reimbursement in Israel for Optune® in Combination with Temozolomide for the Treatment of Newly Diagnosed Glioblastoma

    Novocure (NASDAQ:NVCR) announced today that the State of Israel Ministry of Health has added Optune in combination with temozolomide to the Israeli medical services basket for the treatment of patients with newly

  2. Novocure Announces Fourth Quarter and Full Year 2019 Preliminary Net Revenues and Provides Company Update

    Full year 2019 preliminary net revenues of $351.3 million, representing annual growth of 42 percent compared to 2018 Novocure to present at the 38th Annual J.P. Morgan Healthcare Conference at 10:00 a.m. PST on

  3. Cardiva Medical Appoints Jeri Hilleman to the Company's Board of Directors

    Company to Present at the 38th Annual J.P. Morgan Healthcare Conference Cardiva Medical, Inc., an innovator in the field of vascular closure, today announced the appointment of medical device expert Jeryl ("Jeri")

  4. Zai Lab and Novocure Announce First Patient Enrolled in a Phase 2 Pilot Trial of Tumor Treating Fields Together with Chemotherapy as First-Line Treatment of Gastric Cancer

    Zai Lab Limited (NASDAQ:ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, and Novocure (NASDAQ:NVCR), a global oncology company with a proprietary platform technology called Tumor

  5. Novocure to Participate in the 38th Annual J.P. Morgan Healthcare Conference

    Novocure (NASDAQ:NVCR) will participate in the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020, in San Francisco. William Doyle, Novocure's Executive Chairman, will speak on behalf of the

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 commencement of enrollment announced June 8, 2017.
Optune and bevacizumab
Refractory recurrent glioblastoma (GBM)
Phase 3 interim data 2H 2020. Final data 2022.
Tumor Treating Fields (TTFields) LUNAR
Non-small cell lung cancer (NSCLC)
Phase 3 interim analysis 2022 with final data due 2024.
Tumor Treating Fields (TTFields) - INNOVATE-3
Ovarian cancer
Phase 3 interim analysis 2021. Final data due 2022.
Tumor Treating Fields (TTFields) - PANOVA 3
Pancreatic cancer
Phase 3 data due 2021.
Tumor Treating Fields (TTFields) METIS
Brain Metastases Originating from Non-Small Cell Lung Cancer
Phase 2 abstract September 5, 2018 noted 6.1 months improvement in OS compared with control.
Tumor Treating Fields (TTFields) STELLAR
Mesothelioma
Phase 2 data due 2021.
Tumor Treating Fields (TTFields) - HEPANOVA
Liver cancer

Latest News

  1. Novocure Announces National Reimbursement in Israel for Optune® in Combination with Temozolomide for the Treatment of Newly Diagnosed Glioblastoma

    Novocure (NASDAQ:NVCR) announced today that the State of Israel Ministry of Health has added Optune in combination with temozolomide to the Israeli medical services basket for the treatment of patients with newly

  2. Novocure Announces Fourth Quarter and Full Year 2019 Preliminary Net Revenues and Provides Company Update

    Full year 2019 preliminary net revenues of $351.3 million, representing annual growth of 42 percent compared to 2018 Novocure to present at the 38th Annual J.P. Morgan Healthcare Conference at 10:00 a.m. PST on

  3. Cardiva Medical Appoints Jeri Hilleman to the Company's Board of Directors

    Company to Present at the 38th Annual J.P. Morgan Healthcare Conference Cardiva Medical, Inc., an innovator in the field of vascular closure, today announced the appointment of medical device expert Jeryl ("Jeri")

  4. Zai Lab and Novocure Announce First Patient Enrolled in a Phase 2 Pilot Trial of Tumor Treating Fields Together with Chemotherapy as First-Line Treatment of Gastric Cancer

    Zai Lab Limited (NASDAQ:ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, and Novocure (NASDAQ:NVCR), a global oncology company with a proprietary platform technology called Tumor

  5. Novocure to Participate in the 38th Annual J.P. Morgan Healthcare Conference

    Novocure (NASDAQ:NVCR) will participate in the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020, in San Francisco. William Doyle, Novocure's Executive Chairman, will speak on behalf of the

  6. SI-BONE Names Jeryl ("Jeri") Hilleman to Board of Directors

    SANTA CLARA, Calif., Dec. 04, 2019 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (NASDAQ:SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today

  7. Novocure and the AACR Announce 2nd Annual AACR-Novocure Grants for Tumor Treating Fields Research Program

    The program includes research grants and career development awards totaling more than $2 million over the next three years Novocure (NASDAQ:NVCR) and the American Association for Cancer Research (AACR) announce today

  8. Novocure to Participate in the Evercore ISI 2019 HealthCONx Conference

    Novocure (NASDAQ:NVCR) announced today that William Doyle, Novocure's Executive Chairman, will participate in the Evercore ISI 2019 HealthCONx Conference on December 5, 2019, in Boston. Mr. Doyle's presentation will

  9. Novocure Announces 43 Presentations on Tumor Treating Fields at 24th Annual Meeting of the Society for Neuro-Oncology

    Presentations on Tumor Treating Fields cover a broad and growing range of topics, with nearly 80 percent of presentations prepared by external authors Novocure (NASDAQ:NVCR) today announced 43 presentations on Tumor

  10. Novocure Reports Third Quarter 2019 Financial Results and Provides Company Update

    Quarterly net revenues of $92.1 million, representing 42% growth versus the third quarter 2018 First quarter ever of positive net income with $0.02 in earnings per share Continued clinical progress with four ongoing

  11. Novocure to Report Third Quarter 2019 Financial Results

    Novocure (NASDAQ:NVCR) announced today that it will report financial results for the third quarter 2019 on Thursday, October 31, 2019, before the U.S. financial markets open. Novocure management will host a conference

  12. Novocure Announces 27 Presentations at the American Society for Radiation Oncology 2019 Annual Meeting

    The volume of Tumor Treating Fields presentations marks a record number of abstracts for Novocure at one of the premier meetings for radiation oncologists Highlights include a subgroup analysis of the STELLAR trial by